Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
- PMID: 12200350
- DOI: 10.1182/blood-2002-02-0350
Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
Abstract
Natural killer (NK) cells have held great promise for the immunotherapy of cancer for more than 3 decades. However, to date only modest clinical success has been achieved manipulating the NK cell compartment in patients with malignant disease. Progress in the field of NK cell receptors has revolutionized our concept of how NK cells selectively recognize and lyse tumor and virally infected cells while sparing normal cells. Major families of cell surface receptors that inhibit and activate NK cells to lyse _target cells have been characterized, including killer cell immunoglobulinlike receptors (KIRs), C-type lectins, and natural cytotoxicity receptors (NCRs). Further, identification of NK receptor ligands and their expression on normal and transformed cells completes the information needed to begin development of rational clinical approaches to manipulating receptor/ligand interactions for clinical benefit. Indeed, clinical data suggest that mismatch of NK receptors and ligands during allogeneic bone marrow transplantation may be used to prevent leukemia relapse. Here, we review how NK cell receptors control natural cytotoxicity and novel approaches to manipulating NK receptor-ligand interactions for the potential benefit of patients with cancer.
Similar articles
-
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.Blood. 2004 Jul 1;104(1):170-7. doi: 10.1182/blood-2003-12-4438. Epub 2004 Mar 11. Blood. 2004. PMID: 15016654
-
NK cell receptors and their ligands in leukemia.Leukemia. 2008 Feb;22(2):249-57. doi: 10.1038/sj.leu.2405040. Epub 2007 Nov 29. Leukemia. 2008. PMID: 18046448 Review.
-
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.Biol Blood Marrow Transplant. 2016 Jul;22(7):1290-1298. doi: 10.1016/j.bbmt.2016.04.009. Epub 2016 Apr 16. Biol Blood Marrow Transplant. 2016. PMID: 27090958 Free PMC article. Clinical Trial.
-
Determinants of antileukemia effects of allogeneic NK cells.J Immunol. 2004 Jan 1;172(1):644-50. doi: 10.4049/jimmunol.172.1.644. J Immunol. 2004. PMID: 14688377 Clinical Trial.
-
Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.Semin Cancer Biol. 2006 Oct;16(5):404-11. doi: 10.1016/j.semcancer.2006.07.007. Epub 2006 Jul 8. Semin Cancer Biol. 2006. PMID: 16916611 Review.
Cited by
-
Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.Biol Blood Marrow Transplant. 2015 Sep;21(9):1589-96. doi: 10.1016/j.bbmt.2015.05.002. Epub 2015 May 8. Biol Blood Marrow Transplant. 2015. PMID: 25960307 Free PMC article.
-
Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.Cancers (Basel). 2019 Dec 25;12(1):69. doi: 10.3390/cancers12010069. Cancers (Basel). 2019. PMID: 31881776 Free PMC article. Review.
-
NK cells in allogeneic bone marrow transplantation.Cancer Immunol Immunother. 2003 Sep;52(9):525-34. doi: 10.1007/s00262-003-0378-7. Cancer Immunol Immunother. 2003. PMID: 14627124 Free PMC article. Review.
-
Cervical Cancer Cells Express Markers Associated with Immunosurveillance.J Immunol Res. 2019 May 6;2019:1242979. doi: 10.1155/2019/1242979. eCollection 2019. J Immunol Res. 2019. PMID: 31198791 Free PMC article.
-
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.J Cell Mol Med. 2016 Jul;20(7):1287-94. doi: 10.1111/jcmm.12810. Epub 2016 Mar 23. J Cell Mol Med. 2016. PMID: 27008316 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
